Similar articles

• Clinical experience with the activated clotting time for the control of heparin and protamine therapy during cardiopulmonary bypass.

  Akl BF, Vargas GM, Neal J, Robillard J, Kelly P. Akl BF, et al. J Thorac Cardiovasc Surg. 1980 Jan;79(1):97-102. J Thorac Cardiovasc Surg. 1980. PMID: 7350393
• Postoperative hemostasis.

  Ellison N, Campbell FW, Jobes DR. Ellison N, et al. Semin Thorac Cardiovasc Surg. 1991 Jan;3(1):33-8. Semin Thorac Cardiovasc Surg. 1991. PMID: 2015316 Review. No abstract available.
• Randomized, controlled trial of individualized heparin and protamine management in infants undergoing cardiac surgery with cardiopulmonary bypass.

  Gruenwald CE, Manlhiot C, Chan AK, Crawford-Lean L, Foreman C, Holtby HM, Van Arsdell GS, Richards R, Moriarty H, McCrindle BW. Gruenwald CE, et al. J Am Coll Cardiol. 2010 Nov 23;56(22):1794-802. doi: 10.1016/j.jacc.2010.06.046. J Am Coll Cardiol. 2010. PMID: 21087706 Clinical Trial.
• The role of the activated clotting time in heparin administration and neutralization for cardiopulmonary bypass.

  Esposito RA, Culliford AT, Colvin SB, Thomas SJ, Lackner H, Spencer FC. Esposito RA, et al. J Thorac Cardiovasc Surg. 1983 Feb;85(2):174-85. J Thorac Cardiovasc Surg. 1983. PMID: 6823136
• Safety issues in heparin and protamine administration for extracorporeal circulation.

  Jobes DR. Jobes DR. J Cardiothorac Vasc Anesth. 1998 Apr;12(2 Suppl 1):17-20. J Cardiothorac Vasc Anesth. 1998. PMID: 9583571 Review.